Literature DB >> 23171164

Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases.

Lauren G Aoude1, Claire M Vajdic, Anne Kricker, Bruce Armstrong, Nicholas K Hayward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23171164     DOI： 10.1111/pcmr.12046

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  21 in total

Review 1.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Prognostic parameters in uveal melanoma and their association with BAP1 expression.

Authors:  T Huibertus van Essen; Sake I van Pelt; Mieke Versluis; Inge H G Bronkhorst; Sjoerd G van Duinen; Marina Marinkovic; Wilma G M Kroes; Claudia A L Ruivenkamp; Shruti Shukla; Annelies de Klein; Emine Kiliç; J William Harbour; Gregorius P M Luyten; Pieter A van der Velden; Rob M Verdijk; Martine J Jager
Journal:  Br J Ophthalmol       Date:  2014-08-21       Impact factor: 4.638

3.  P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma.

Authors:  Hui Pan; Hongyan Ni; LeiLei Zhang; Yue Xing; Jiayan Fan; Peng Li; Tianyuan Li; Renbing Jia; Shengfang Ge; He Zhang; Xianqun Fan
Journal:  Tumour Biol       Date:  2016-07-28

4.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

Authors:  Francine Baumann; Erin Flores; Andrea Napolitano; Shreya Kanodia; Emanuela Taioli; Harvey Pass; Haining Yang; Michele Carbone
Journal:  Carcinogenesis       Date:  2014-11-07       Impact factor: 4.944

Review 5.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.

Authors:  K Rai; R Pilarski; C M Cebulla; M H Abdel-Rahman
Journal:  Clin Genet       Date:  2015-07-14       Impact factor: 4.438

Review 6.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.

Authors:  Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

Review 7.  Update on the targeted therapy of melanoma.

Authors:  Douglas B Johnson; Jeffrey A Sosman
Journal:  Curr Treat Options Oncol       Date:  2013-06

8.  A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

Authors:  Megan N Farley; Laura S Schmidt; W Marston Linehan; James Brugarolas; Jessica L Mester; Samuel Pena-Llopis; Andrea Pavia-Jimenez; Alana Christie; Cathy D Vocke; Christopher J Ricketts; James Peterson; Lindsay Middelton; Lisa Kinch; Nick Grishin; Maria J Merino; Adam R Metwalli; Chao Xing; Xian-Jin Xie; Patricia L M Dahia; Charis Eng
Journal:  Mol Cancer Res       Date:  2013-05-24       Impact factor: 5.852

Review 9.  Uveal melanoma: From diagnosis to treatment and the science in between.

Authors:  Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

10.  BAP1 and cancer.

Authors:  Michele Carbone; Haining Yang; Harvey I Pass; Thomas Krausz; Joseph R Testa; Giovanni Gaudino
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.